

BRIEF INFORMATION
about the first domestic inactivated vaccine QazVac (QazCovid-in) against
coronavirus infection COVID-19, developed by scientists of
RSE "Research Institute for Biological Safety Problems" of the
Committee of Science of the Ministry of Education and Science of the
Republic of Kazakhstan

The first domestic inactivated vaccine QazCovid-in (official name) (QazVac (trade name)) against SARS-CoV-2

Year of development – April-May 2020

Vaccine composition is the whole-virion SARS-CoV-2 virus obtained in VERO cell culture (approved by the World Health Organization), inactivated with formaldehyde, passed the 4th degree of purification, containing an immunostimulator (adjuvant) aluminum hydroxide (approved by the World Health Organization)

Vaccine dose is 0.5 mL

The method of administration is intramuscularly (into the deltoid muscle of the arm)

The frequency of administration is twice with an interval of 21 days

Vaccine packaging – 1 dose (0.5 mL), 2 doses (1.0 mL), 3 doses (1.5 mL), 5 doses (2.5 mL)

Vaccine storage temperature – plus 2-8 °C

Transportation conditions – by all types of transport in compliance with the temperature regime plus 2-8 °C

Clinical trials – phase I of clinical trials of the domestic QazVac vaccine were conducted on 44 volunteers in Almaty; phase II – 200 volunteers in Almaty; phase III – 3000 volunteers in Almaty and Taraz. According to the results of phase I and II clinical trials, the domestic inactivated QazVac (QazCovid-in) vaccine has proven complete safety, the vaccine forms a strong immunity against coronavirus infection. Currently, the results of the phase III of clinical trials of the domestic QazVac vaccine are under state examination at the Ministry of Health of the Republic of Kazakhstan. The official conclusion on the examination has not yet been received.

WHO registration – On May 15, 2020, the COVID-19 inactivated vaccine QazVac on the WHO website as a candidate vaccine

Registration in Kazakhstan – temporary registration for a period of 18 months

Production – since April, 300 thousand doses of the domestic QazVac vaccine have been produced and shipped to the hubs of SK-Pharmacy LLP

Advantages – the whole-virion inactivated virus contained in the vaccine, consisting of a complete set of proteins, ensures the formation of a high antibody response and persistent immunity against SARS-CoV-2, as well as against other strains of the virus. In addition, the methods of delivery of the QazVac vaccine do not require complex refrigeration units, they are transported in a refrigerator at plus 2-8 °C.